Sanofi enters strategic collaboration with Recludix Pharma

Recludix Pharma announced that the company has entered into a strategic collaboration with Sanofi to develop and commercialize first-in-class oral small molecule STAT6 inhibitors for patients with immunological and inflammatory diseases. Under the partnership, Sanofi will have global rights to small molecule STAT6 inhibitors. Recludix will advance STAT6 inhibitors from preclinical research and development until the start of Phase 2 clinical trials. Sanofi will assume worldwide clinical development and commercialization responsibilities thereafter. Recludix has the option to participate in U.S. profit/loss share, which includes the ability to share equally in the costs, profits and losses, and to certain co-promotion activities for the partnered product in the U.S. Recludix will receive $125 million in near-term payments, and additionally, Recludix may receive more than $1.2 billion in potential development, regulatory and sales milestones, as well as up to double-digit royalties on possible future product sales.